Khiron Life Sciences Corp. has launched its teleconsultation services to meet essential patient needs during the current COVID-19 pandemic.
- Starting April 1st, Company’s virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis
- Teleconsultation service anticipated to quickly expand to meet potential growing demand for telehealth services, including Company’s 120,000 patients from its ILANS and Zerenia clinics
- Khiron has already received initial approvals from third party payers to include teleconsultation services in its insured service offerings
- Khiron and its clinics continue to be operational during COVID-19 pandemic under an exemption decreed by the Government of Colombia, without any requirement for further authorization
- Virtual medical services complement Khiron’s delivery service that is already successfully delivering prescriptions directly to patients’ homes
- Telemedicine acceptance increasing rapidly, with average US compound visit growth of 52% per year from 2005 – 2014 (Source: JAMA)
- Khiron is the first company authorized to sell medical cannabis in Colombia
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN, OTCQX:KHRNF, Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced the Company has launched its teleconsultation services, leveraging its medical team and existing patient network to meet essential patient needs during the current COVID-19 pandemic. From an initial beta launch, the Company anticipates rapidly expanding services across its entire patient network amidst the growing acceptance of telemedicine services.
“We are in unprecedented times and so it is more important than ever for Khiron to continue to meet the medical needs of our patients. The launch of our teleconsultation services was made possible with our on-staff doctor expertise and established patient network, allowing us to move swiftly to continue to deliver clinical services and prescriptions for medical cannabis and other drugs, directly to the patients who need it,” comments Alvaro Torres, Khiron CEO and director.
Khiron’s teleconsultation services launch on April 1st, with an initial beta phase to serve priority patient needs. Expanded services will launch in the coming weeks to be fully available to patients across Colombia, including to the Company’s over 120,000 patient network established through its ILANS and Zerenia medical facilities. The Company is working closely with third party payers to ensure the program meets their insurance coverage requirements.
“Khiron has established contingency plans in place for all our facilities, including our medical facilities which are essential to serving the community. Those plans were put into action and our medical facilities and supply chain remain operating within strict government guidelines established as a result of the current pandemic. I commend our frontline staff for their continued hard work and commitment to meeting patient needs during this difficult time,” said Mr. Torres.
Khiron is the first, and currently the only, Company authorized to sell medical cannabis in Colombia, having recently obtained certification of Good Elaboration Practices (GEP) for Magistral Preparations with Cannabis. Under Colombian regulations, GEP is a manufacturing and processing certification that is a mandatory requirement for commercializing customized medical cannabis prescriptions known as magistral preparations.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The Company delivers best in class regulatory compliance, has the first approved line of CBD cosmetic products on shelf in Colombia, and is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis in the country.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram @khironlife
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.